Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MOK | Q9UQ07 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30163497 | 0.86 | MAPK1 (0.48) | MAPK1HPGDLMNAMOKSMN1; SMN2 | |
| SCHEMBL24977251 | 0.86 | MAPK1 (0.48) | MAPK1HPGDLMNAMOKSMN1; SMN2 | |
| SCHEMBL31429082 | 0.81 | HPGD (0.62) | HPGDSMN1; SMN2MYCPKMGAA | |
| SCHEMBL31428815 | 0.81 | HPGD (0.52) | HPGDSMN1; SMN2MYCPKMGAA | |
| SCHEMBL31428513 | 0.81 | PDCD1 (0.53) | HPGDLMNACNR1PKMKDM4E | |
| SCHEMBL31428810 | 0.80 | HPGD (0.48) | HPGDMYCCNR1PKMGAA | |
| SCHEMBL31428523 | 0.80 | GRM2 (0.51) | HPGDMYCPKMGAAKDM4E | |
| SCHEMBL31428834 | 0.79 | GRM2 (0.48) | HPGDSMN1; SMN2MYCPKMGAA | |
| SCHEMBL31428625 | 0.79 | HPGD (0.49) | HPGDSMN1; SMN2MYCCNR1PKM | |
| SCHEMBL24975802 | 0.78 | HPGD (0.46) | HPGDSMN1; SMN2MYCPKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | MAPK1 140/4885HPGD 4233/4885LMNA 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.